Literature DB >> 23467507

Isolated fever induced by mesalamine treatment.

Rita Slim1, Joseph Amara, Roy Nasnas, Khalil Honein, Joseph Bou Jaoude, Cesar Yaghi, Fady Daniel, Raymond Sayegh.   

Abstract

Adverse reactions to mesalamine, a treatment used to induce and maintain remission in inflammatory bowel diseases, particularly ulcerative colitis, have been described in the literature as case reports. This case illustrates an unusual adverse reaction. Our patient developed an isolated fever of unexplained etiology, which was found to be related to mesalamine treatment. A 22-year-old patient diagnosed with ulcerative colitis developed a fever with rigors and anorexia 10 d after starting oral mesalamine while his colitis was clinically resolving. Testing revealed no infection. A mesalamine-induced fever was considered, and treatment was stopped, which led to spontaneous resolution of the fever. The diagnosis was confirmed by reintroducing the mesalamine. One year later, this side effect was noticed again in the same patient after he was administered topical mesalamine. This reaction to mesalamine seems to be idiosyncratic, and the mechanism that induces fever remains unclear. Fever encountered in the course of a mesalamine treatment in ulcerative colitis must be considered a mesalamine-induced fever when it cannot be explained by the disease activity, an associated extraintestinal manifestation, or an infectious etiology.

Entities:  

Keywords:  5-aminosalicylic acid; Adverse reactions; Fever; Mesalamine; Side effects

Mesh:

Substances:

Year:  2013        PMID: 23467507      PMCID: PMC3582006          DOI: 10.3748/wjg.v19.i7.1147

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  12 in total

1.  Desensitization after fever induced by mesalazine.

Authors:  M A Gonzalo; M M Alcalde; J M García; M I Alvarado; L Fernández
Journal:  Allergy       Date:  1999-11       Impact factor: 13.146

2.  Is mesalamine safe?

Authors:  Kenneth W Schroeder
Journal:  Gastroenterol Hepatol (N Y)       Date:  2007-11

3.  Mesalamine-associated hypersensitivity myocarditis in ulcerative colitis.

Authors:  Sundae Stelts; Marian H Taylor; Jean Nappi; Adrian B Van Bakel
Journal:  Ann Pharmacother       Date:  2008-04-22       Impact factor: 3.154

4.  Mesalamine induced symptom exacerbation of ulcerative colitis: Case report and brief discussion.

Authors:  Maneesh Kumar Gupta; Scott Pollack; John J Hutchings
Journal:  World J Gastrointest Pharmacol Ther       Date:  2010-12-06

5.  Lack of cross-reactivity between 5-aminosalicylic acid-based drugs: a case report and review of the literature.

Authors:  Shiang-Ju Kung; Cuckoo Choudhary; Stephen J McGeady; John R Cohn
Journal:  Ann Allergy Asthma Immunol       Date:  2006-09       Impact factor: 6.347

Review 6.  Can a drug-induced pulmonary hypersensitivity reaction be dose-dependent? A case with mesalamine.

Authors:  P Sossai; M G Cappellato; S Stefani
Journal:  Mt Sinai J Med       Date:  2001-11

Review 7.  5-aminosalicylic acid is an attractive candidate agent for chemoprevention of colon cancer in patients with inflammatory bowel disease.

Authors:  Yang Cheng; Pierre Desreumaux
Journal:  World J Gastroenterol       Date:  2005-01-21       Impact factor: 5.742

Review 8.  Adverse events in patients treated with 5-aminosalicyclic acid: 1993-1994 pharmacovigilance report for Pentasa in France.

Authors:  P Marteau; F Nelet; M Le Lu; C Devaux
Journal:  Aliment Pharmacol Ther       Date:  1996-12       Impact factor: 8.171

Review 9.  Systematic review: short-term adverse effects of 5-aminosalicylic acid agents in the treatment of ulcerative colitis.

Authors:  E V Loftus; S V Kane; D Bjorkman
Journal:  Aliment Pharmacol Ther       Date:  2004-01-15       Impact factor: 8.171

10.  Acute Pancreatitis due to pH-Dependent Mesalazine That Occurred in the Course of Ulcerative Colitis.

Authors:  Yoshinori Arai; Seiji Arihiro; Daisuke Ide; Isao Odagi; Munenori Itagaki; Nobuhiko Komoike; Yutaka Nakao; Kazuki Takakura; Masayuki Saruta; Mika Matsuoka; Tomohiro Kato; Hisao Tajiri
Journal:  Case Rep Gastroenterol       Date:  2011-10-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.